Needham estimates medtech sales grew less than expected in Q1, but that Boston Scientific (NYSE:BSX), CONMED (NYSE:CNMD), ResMed (NYSE:RMD) and Surmodics (NASDAQ:SRDX) should still be able to beat the...
Source LinkNeedham estimates medtech sales grew less than expected in Q1, but that Boston Scientific (NYSE:BSX), CONMED (NYSE:CNMD), ResMed (NYSE:RMD) and Surmodics (NASDAQ:SRDX) should still be able to beat the...
Source Link
Comments